Biogen (NASDAQ:BIIB – Free Report) had its price target boosted by Robert W. Baird from $294.00 to $300.00 in a research ...

Research analysts at Wolfe Research initiated coverage on shares of Biogen (NASDAQ:BIIB – Get Free Report) in a report issued ...

On Friday, Biogen Inc (BIIB) stock saw a decline, ending the day at $159.99 which represents a decrease of $-4.90 or -2.97% from the prior close of $164.89. The stock opened at $165.46 and touched a ...

Roche’s Evrysdi (risdiplam) is the market leader among the drugs for spinal muscular atrophy (SMA). Biogen’s Spinraza ...

Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

On Thursday, Biogen Inc (BIIB) stock saw a decline, ending the day at $164.89 which represents a decrease of $-0.90 or -0.54% from the prior close of $165.79. The stock opened at $165 and touched a ...

Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report) and keeping the price target at ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Fintel reports that on November 14, 2024, Citigroup initiated coverage of Biogen (NasdaqGS:BIIB) with a Neutral ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Biogen (NasdaqGS:BIIB) with a Peer Perform ...

Deep-pocketed investors have adopted a bearish approach towards Biogen BIIB, and it's something market players shouldn't ...